Amlodipine and Trazodone Interaction: What Patients and Prescribers Need to Know

Amlodipine (brand name Norvasc) is a dihydropyridine calcium channel blocker used for hypertension and angina. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI), FDA-approved as an antidepressant and widely used off-label at low doses for insomnia. Neither drug is a peptide or a compounded product; both are standard oral small-molecule prescription medications with long marketing histories.

The core, quotable answer: amlodipine lowers blood pressure by blocking calcium channels in vascular smooth muscle, while trazodone lowers blood pressure separately through alpha-1 adrenergic blockade; because these are two different mechanisms converging on the same effect, their combined use carries a real but manageable risk of orthostatic hypotension, particularly in adults over 65 during the first two weeks of co-administration. This is a pharmacodynamic interaction with a plausible, unquantified pharmacokinetic contribution from trazodone's weak CYP3A4 inhibition. No regulatory label lists this combination as contraindicated, and standard practice is monitoring rather than avoidance.

Does this combination need to be avoided?

No. Neither the amlodipine label nor the trazodone label lists the other drug as contraindicated. The interaction is best described as moderate and monitorable: predictable in direction, manageable with dose titration, and most concerning in older adults or anyone already near their lowest tolerated blood pressure. This is site judgment based on how the two mechanisms are known to behave, not a specific finding from a dedicated amlodipine-trazodone interaction trial. We are not aware of a controlled pharmacokinetic study of the two drugs given together, and readers or clinicians who need that specific data point should search for it directly rather than assume one exists.

Why the two drugs interact

Amlodipine's blood-pressure effect

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle, reducing peripheral vascular resistance. It has a long terminal half-life, commonly cited as roughly 30 to 50 hours, which means it takes about a week for a new dose to reach steady-state plasma levels and for its full blood-pressure effect to appear. The FDA prescribing label for Norvasc describes a dose-dependent reduction in seated blood pressure; readers who need the exact mmHg figures at each dose should check the current label directly, since label text is revised over time and we have not independently re-verified every number against the live document.

Amlodipine is metabolized primarily by the CYP3A4 enzyme. The label notes that strong CYP3A4 inhibitors can meaningfully raise amlodipine plasma exposure, which is the pharmacologic basis for caution with any CYP3A4-inhibiting drug, including weaker inhibitors like trazodone (2011 label, current as of the date on the document; confirm against the live FDA label before citing a specific percentage).

Trazodone's blood-pressure effect

Trazodone is often thought of only as a sedating antidepressant, but its alpha-1 adrenergic blockade is pharmacologically significant on its own. That blockade relaxes arteriolar smooth muscle and lowers blood pressure independent of trazodone's serotonergic action. The FDA label for trazodone hydrochloride lists orthostatic hypotension and syncope as reported adverse effects and states that concomitant antihypertensive therapy may require a dose reduction of the antihypertensive. That label language is the clearest, most directly supportable evidence anchor for this entire page.

The plausible pharmacokinetic layer

Trazodone is metabolized in part through CYP3A4, and in vitro pharmacology work has described trazodone and its metabolite as weak inhibitors of that enzyme. Because amlodipine clearance depends on CYP3A4, a weak inhibitor could theoretically slow amlodipine clearance and modestly raise its plasma levels. This is pharmacologically plausible and consistent with how CYP3A4 inhibition behaves generally, but we do not have a verified, dedicated pharmacokinetic study quantifying how much trazodone specifically raises amlodipine exposure in practice. Any specific percentage attached to this claim should be treated as unconfirmed until checked against the primary pharmacology literature.

Evidence-status assessment

What to monitor, and when

Blood pressure, seated and standing. Check before starting the second drug, again about one to two weeks after starting trazodone or after any dose change, and after any amlodipine dose change. A standing systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, with or without symptoms, is the standard definition of orthostatic hypotension and warrants a dose review.

Resting heart rate. Both drugs can produce reflex tachycardia through different pathways. A sustained resting heart rate elevation at follow-up visits is worth investigating rather than dismissing.

Fall and near-syncope screening. Ask directly about dizziness on standing, graying-out of vision, or falls since the last visit, especially in patients over 65. The CDC's STEADI program provides a structured fall-risk screening approach that clinicians can use in this population regardless of which specific medications are involved.

Hepatic function. Both drugs are hepatically metabolized. Patients with moderate to severe hepatic impairment clear both more slowly, which is a general pharmacokinetic principle rather than a finding specific to this pair.

Practical prescribing sequence

When trazodone is being added to an existing amlodipine regimen, or amlodipine is being added to existing trazodone therapy, the following sequence reflects standard cautious prescribing for two additive antihypertensive-acting drugs. It is site judgment built from each drug's individually labeled effects, not a guideline-endorsed protocol specific to this pair.

1. Check seated and standing blood pressure before starting the second drug. If standing systolic pressure is already below roughly 100 to 110 mmHg, address that before adding a second blood-pressure-lowering agent.
2. Review the full medication list for other antihypertensives, diuretics, or CYP3A4 inhibitors (certain azole antifungals, macrolide antibiotics) that would compound either effect.
3. Start the new drug at its lowest practical dose: trazodone at 50 mg at bedtime is a common low starting dose for insomnia, and amlodipine is commonly started at 2.5 to 5 mg depending on the clinical situation.
4. Recheck blood pressure roughly seven to ten days later, since amlodipine's long half-life means its effect is still accumulating during that window.
5. Document the interaction, the monitoring plan, and the counseling given, so the next prescriber or pharmacist can see the reasoning.

This is a decision-support sequence, not an individualized dosing instruction. Actual starting doses and titration schedules should be set by the prescribing clinician based on the individual patient's blood pressure, renal and hepatic function, and other medications.

Patient counseling points

Rise slowly. Moving from lying to sitting, pausing briefly, then standing reduces the chance of orthostatic symptoms. This is a standard fall-prevention measure recommended in general geriatric and hypertension guidance, not a finding unique to this drug pair.

Take trazodone at bedtime if it is prescribed for sleep. Its hypotensive effect peaks a couple of hours after dosing; taking it at night means the peak effect largely occurs while the patient is already lying down.

Avoid alcohol. Alcohol is independently vasodilatory and sedating and can amplify the hypotensive effect of either drug.

Know the warning signs. Lightheadedness on standing, visual graying-out, a racing heart, or an actual fall are reasons to sit or lie down immediately and to contact the prescribing clinician the same day. Chest pain, fainting with injury, or persistent low blood pressure with confusion are reasons to seek urgent or emergency care rather than waiting for a routine appointment.

Do not adjust doses without guidance. Amlodipine's long half-life means that a dose change will not show its full effect on blood pressure for several days. Patients who feel dizzy and independently cut their amlodipine dose in half may not see improvement quickly and can become confused about which drug is causing the problem.

Alternatives worth discussing with a prescriber

If trazodone is being used specifically for insomnia and blood pressure control is already tight, other options carry a different interaction profile, though the tradeoffs (sedation, weight effects, cost, and effectiveness) differ from trazodone's and should be weighed individually with a prescriber rather than assumed to be simply "safer":

• Low-dose doxepin (in the 3 to 6 mg range) is FDA-approved for insomnia and works mainly through histamine H1 blockade at that dose, with less alpha-1 adrenergic activity than trazodone.
• Ramelteon, a melatonin receptor agonist, does not share trazodone's alpha-1 blocking mechanism and is not expected to add to amlodipine's blood-pressure-lowering effect.
• Mirtazapine is also sedating but works through a different receptor profile; it is not free of cardiovascular considerations and should not be assumed automatically safer without individual review.

Switching from amlodipine to a non-dihydropyridine calcium channel blocker (diltiazem or verapamil) to solve this specific interaction is generally not the right move, because both of those drugs are themselves significant CYP3A4 inhibitors and would raise trazodone levels rather than avoid an interaction.

What the guidelines say

The 2017 ACC/AHA hypertension guideline recommends reviewing a patient's full medication list for drug effects on blood pressure as part of routine hypertension management. Trazodone's alpha-1 blocking activity places it among the drugs worth flagging in that review, though the guideline addresses medication review broadly rather than naming this specific drug pair.

Separately, the American Geriatrics Society's Beers Criteria, a widely used guideline identifying potentially inappropriate medications in older adults, has flagged trazodone as a drug associated with increased fall risk in that population and generally recommends caution or safer alternatives for insomnia when they exist. When trazodone is continued in an older patient who is also on amlodipine, documenting the rationale and monitoring plan is consistent with that guideline's intent, even though it does not name amlodipine specifically.

What is established, what is plausible, and what is not established

Established: Trazodone can cause orthostatic hypotension on its own, as stated in its FDA label. Amlodipine's blood-pressure effect is dose-dependent and accumulates over roughly a week due to its long half-life, as stated in its FDA label. Amlodipine is a CYP3A4 substrate, and strong CYP3A4 inhibitors raise its levels per the label.

Plausible but not established as a quantified combination effect: Trazodone's weak CYP3A4 inhibition modestly raising amlodipine exposure. Additive orthostatic hypotension risk being highest in the first one to two weeks of co-administration. Older adults being disproportionately affected by this specific pair, as opposed to by antihypertensive-plus-sedating-drug combinations generally.

Not established on the evidence available here: Any specific numeric rate of falls, syncope, or emergency visits attributable to the amlodipine-trazodone combination specifically. A precise percentage increase in amlodipine AUC caused by trazodone. Formal severity classification language beyond what commercial interaction databases publish, which should be checked live rather than assumed static.